Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Activated recombinant factor VII in cardiac surgery.

Marie E Steiner1, Nigel S Key, Jerrold H Levy

  • 1Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.

Current Opinion in Anaesthesiology
|March 15, 2006
PubMed
Summary

Activated recombinant factor VII shows promise for managing severe bleeding after cardiac surgery. Further randomized trials are needed to confirm its effectiveness and safety in reducing blood loss and transfusion needs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association of estimated citrate load with frozen plasma versus four-factor prothrombin complex concentrate for coagulopathy after cardiac surgery: a <i>post hoc</i> exploratory analysis of the FARES-II randomised controlled trial.

BJA open·2026
Same author

Management of anticoagulation in patients with heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass: guidance from the ISTH SSC on Perioperative and Critical Care Haemostasis and Thrombosis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Response to the comment by Gando on the updated definition and scoring of disseminated intravascular coagulation.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Development, validation, and user-centric evaluation of an interpretable machine learning decision support tool for the preoperative prediction of mild bleeding disorders (MBD-Check): a prospective diagnostic prediction study.

The Lancet. Digital health·2026
Same author

How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Designing biomarker-selected international trials in sepsis-associated coagulopathy.

Journal of thrombosis and haemostasis : JTH·2026

Area of Science:

  • Cardiology
  • Hematology
  • Surgical Medicine

Background:

  • Severe bleeding is a significant risk following cardiac surgery, often persisting despite current pharmacological treatments.
  • Reducing blood loss and transfusion requirements remain critical challenges in postoperative cardiac care.

Purpose of the Study:

  • To review the potential of activated recombinant factor VII (rFVIIa) as a therapeutic option for refractory bleeding after cardiac surgery.
  • To evaluate the current evidence for rFVIIa in managing postoperative bleeding states.

Main Methods:

  • Review of existing small, uncontrolled case series and published reports on rFVIIa use in cardiac surgery patients.
  • Analysis of reported outcomes regarding blood loss, transfusion requirements, and adverse events.

Related Experiment Videos

Main Results:

  • Case series suggest rFVIIa may reduce bleeding and transfusion needs in some adult and pediatric patients post-cardiopulmonary bypass.
  • Optimal dosing, timing of administration, and frequency of adverse events for rFVIIa remain undetermined.

Conclusions:

  • Activated recombinant factor VII appears promising for uncontrolled bleeding after cardiopulmonary bypass.
  • Randomized, placebo-controlled trials are essential to validate the efficacy and safety of rFVIIa in this context.